JP2008520644A - オクタヒドロピロロ［３，４−ｃ］ピロール誘導体 - Google Patents

オクタヒドロピロロ［３，４−ｃ］ピロール誘導体 Download PDF

Info

Publication number: JP2008520644A
Authority: JP; Japan
Prior art keywords: formula; compound; methyl; title compound; give
Prior art date: 2004-11-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2007542155A

Other languages

English (en)

Japanese (ja)

Inventor

レイン，シャーロット・アリス・ルイス

プライス，デーヴィッド・アンソニー

Original Assignee

ファイザー・インク

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-24

Filing date

2005-11-10

Publication date

2008-06-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35985757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008520644(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-24 Priority claimed from EP04106044A external-priority patent/EP1671972A1/en

2005-11-10 Application filed by ファイザー・インク filed Critical ファイザー・インク

2008-06-19 Publication of JP2008520644A publication Critical patent/JP2008520644A/ja

Status Pending legal-status Critical Current

Links

QFCMBRXRVQRSSF-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole Chemical class C1NCC2CNCC21 QFCMBRXRVQRSSF-UHFFFAOYSA-N 0.000 title abstract description 5
239000000203 mixture Substances 0.000 claims abstract description 70
238000004519 manufacturing process Methods 0.000 claims abstract description 63
150000001875 compounds Chemical class 0.000 claims description 233
238000000034 method Methods 0.000 claims description 103
-1 trifluoromethoxy, hydroxy Chemical group 0.000 claims description 53
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 48
150000003839 salts Chemical class 0.000 claims description 41
ZVFSYTFFWGYEMM-UHFFFAOYSA-N 2-(trichloromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(C(Cl)(Cl)Cl)=NC2=C1 ZVFSYTFFWGYEMM-UHFFFAOYSA-N 0.000 claims description 31
239000003814 drug Substances 0.000 claims description 28
229910052757 nitrogen Inorganic materials 0.000 claims description 25
229910021529 ammonia Inorganic materials 0.000 claims description 23
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
239000012453 solvate Substances 0.000 claims description 19
239000003446 ligand Substances 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 15
150000001412 amines Chemical class 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
201000010099 disease Diseases 0.000 claims description 13
229940079593 drug Drugs 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 11
239000003112 inhibitor Substances 0.000 claims description 10
239000005557 antagonist Substances 0.000 claims description 7
125000001153 fluoro group Chemical group F* 0.000 claims description 7
125000005843 halogen group Chemical group 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
230000000172 allergic effect Effects 0.000 claims description 6
208000010668 atopic eczema Diseases 0.000 claims description 6
206010006451 bronchitis Diseases 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
206010020751 Hypersensitivity Diseases 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
206010039085 Rhinitis allergic Diseases 0.000 claims description 5
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
201000010105 allergic rhinitis Diseases 0.000 claims description 5
230000007815 allergy Effects 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 5
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 5
229940044551 receptor antagonist Drugs 0.000 claims description 5
239000002464 receptor antagonist Substances 0.000 claims description 5
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims description 4
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims description 4
206010020565 Hyperaemia Diseases 0.000 claims description 4
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 4
206010028735 Nasal congestion Diseases 0.000 claims description 4
102000048176 Prostaglandin-D synthases Human genes 0.000 claims description 4
108030003866 Prostaglandin-D synthases Proteins 0.000 claims description 4
206010039094 Rhinitis perennial Diseases 0.000 claims description 4
208000036284 Rhinitis seasonal Diseases 0.000 claims description 4
206010064948 Viral rhinitis Diseases 0.000 claims description 4
230000008369 airway response Effects 0.000 claims description 4
229960005127 montelukast Drugs 0.000 claims description 4
150000002825 nitriles Chemical class 0.000 claims description 4
208000037916 non-allergic rhinitis Diseases 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
206010006458 Bronchitis chronic Diseases 0.000 claims description 3
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 3
201000003883 Cystic fibrosis Diseases 0.000 claims description 3
201000004624 Dermatitis Diseases 0.000 claims description 3
206010014561 Emphysema Diseases 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims description 3
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
229960001803 cetirizine Drugs 0.000 claims description 3
208000007451 chronic bronchitis Diseases 0.000 claims description 3
208000013804 chronic ethmoidal sinusitis Diseases 0.000 claims description 3
201000010761 chronic ethmoiditis Diseases 0.000 claims description 3
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 3
229960003592 fexofenadine Drugs 0.000 claims description 3
239000000938 histamine H1 antagonist Substances 0.000 claims description 3
239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 3
239000003395 histamine H3 receptor antagonist Substances 0.000 claims description 3
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 3
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 3
229960003088 loratadine Drugs 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 3
208000023504 respiratory system disease Diseases 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
206010039083 rhinitis Diseases 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 claims description 2
108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 claims description 2
229940122086 Adenosine A2a receptor agonist Drugs 0.000 claims description 2
206010005063 Bladder pain Diseases 0.000 claims description 2
102000015554 Dopamine receptor Human genes 0.000 claims description 2
108050004812 Dopamine receptor Proteins 0.000 claims description 2
229940122858 Elastase inhibitor Drugs 0.000 claims description 2
206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
206010020853 Hypertonic bladder Diseases 0.000 claims description 2
208000001953 Hypotension Diseases 0.000 claims description 2
239000003458 I kappa b kinase inhibitor Substances 0.000 claims description 2
108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 2
229940122696 MAP kinase inhibitor Drugs 0.000 claims description 2
206010057672 Male sexual dysfunction Diseases 0.000 claims description 2
102000005741 Metalloproteases Human genes 0.000 claims description 2
108010006035 Metalloproteases Proteins 0.000 claims description 2
229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 claims description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
108091007960 PI3Ks Proteins 0.000 claims description 2
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 2
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 2
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims description 2
102000009389 Prostaglandin D receptors Human genes 0.000 claims description 2
108050000258 Prostaglandin D receptors Proteins 0.000 claims description 2
102100024212 Prostaglandin D2 receptor Human genes 0.000 claims description 2
229940122913 Prostaglandin D2 receptor antagonist Drugs 0.000 claims description 2
229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims description 2
102000003141 Tachykinin Human genes 0.000 claims description 2
206010054094 Tumour necrosis Diseases 0.000 claims description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
239000002465 adenosine A2a receptor agonist Substances 0.000 claims description 2
239000000048 adrenergic agonist Substances 0.000 claims description 2
239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims description 2
239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims description 2
229940126157 adrenergic receptor agonist Drugs 0.000 claims description 2
239000000556 agonist Substances 0.000 claims description 2
230000000954 anitussive effect Effects 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000000259 anti-tumor effect Effects 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
239000003434 antitussive agent Substances 0.000 claims description 2
229940124584 antitussives Drugs 0.000 claims description 2
206010003119 arrhythmia Diseases 0.000 claims description 2
230000006793 arrhythmia Effects 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
230000000747 cardiac effect Effects 0.000 claims description 2
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 2
239000000812 cholinergic antagonist Substances 0.000 claims description 2
229940111134 coxibs Drugs 0.000 claims description 2
229940109248 cromoglycate Drugs 0.000 claims description 2
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 2
230000010250 cytokine signaling pathway Effects 0.000 claims description 2
239000000850 decongestant Substances 0.000 claims description 2
230000004064 dysfunction Effects 0.000 claims description 2
239000003602 elastase inhibitor Substances 0.000 claims description 2
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
239000003172 expectorant agent Substances 0.000 claims description 2
229960002464 fluoxetine Drugs 0.000 claims description 2
229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
230000002757 inflammatory effect Effects 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims description 2
229940043355 kinase inhibitor Drugs 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims description 2
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 2
230000000510 mucolytic effect Effects 0.000 claims description 2
229940066491 mucolytics Drugs 0.000 claims description 2
239000003681 muscarinic M3 receptor antagonist Substances 0.000 claims description 2
208000031225 myocardial ischemia Diseases 0.000 claims description 2
239000003901 neurotransmitter uptake inhibitor Substances 0.000 claims description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
208000020629 overactive bladder Diseases 0.000 claims description 2
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 2
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 2
229960002296 paroxetine Drugs 0.000 claims description 2
230000037361 pathway Effects 0.000 claims description 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 2
239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
208000017520 skin disease Diseases 0.000 claims description 2
229940127230 sympathomimetic drug Drugs 0.000 claims description 2
108060008037 tachykinin Proteins 0.000 claims description 2
229960000278 theophylline Drugs 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
229960005356 urokinase Drugs 0.000 claims description 2
230000003639 vasoconstrictive effect Effects 0.000 claims description 2
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 2
229960000607 ziprasidone Drugs 0.000 claims description 2
206010013975 Dyspnoeas Diseases 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
208000012871 acute dyspnea Diseases 0.000 claims 1
239000013566 allergen Substances 0.000 claims 1
230000036543 hypotension Effects 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
239000007787 solid Substances 0.000 description 101
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
238000005481 NMR spectroscopy Methods 0.000 description 63
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 60
239000000243 solution Substances 0.000 description 48
238000002360 preparation method Methods 0.000 description 47
239000002904 solvent Substances 0.000 description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
238000009472 formulation Methods 0.000 description 27
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
238000006243 chemical reaction Methods 0.000 description 20
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 18
239000012043 crude product Substances 0.000 description 18
239000000463 material Substances 0.000 description 18
102000005962 receptors Human genes 0.000 description 17
108020003175 receptors Proteins 0.000 description 17
239000003826 tablet Substances 0.000 description 17
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
238000012512 characterization method Methods 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
230000035484 reaction time Effects 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
239000012074 organic phase Substances 0.000 description 13
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000002552 dosage form Substances 0.000 description 12
238000003818 flash chromatography Methods 0.000 description 12
239000000741 silica gel Substances 0.000 description 12
229910002027 silica gel Inorganic materials 0.000 description 12
229910052938 sodium sulfate Inorganic materials 0.000 description 12
235000011152 sodium sulphate Nutrition 0.000 description 12
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
229940002612 prodrug Drugs 0.000 description 10
239000000651 prodrug Substances 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
229940124597 therapeutic agent Drugs 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
238000001914 filtration Methods 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
238000013270 controlled release Methods 0.000 description 8
229960001340 histamine Drugs 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000002243 precursor Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
YQURLNGUWNDBIR-KNVOCYPGSA-N (3as,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole Chemical compound C1NC[C@@H]2CN(C)C[C@@H]21 YQURLNGUWNDBIR-KNVOCYPGSA-N 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
238000010992 reflux Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
230000003111 delayed effect Effects 0.000 description 6
239000010408 film Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
238000013268 sustained release Methods 0.000 description 6
239000012730 sustained-release form Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
229920000858 Cyclodextrin Polymers 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
125000001309 chloro group Chemical group Cl* 0.000 description 5
238000009833 condensation Methods 0.000 description 5
230000005494 condensation Effects 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
239000006260 foam Substances 0.000 description 5
OGBINJLTBZWRRB-UHFFFAOYSA-N methyl 2,2,2-trichloroethanimidate Chemical compound COC(=N)C(Cl)(Cl)Cl OGBINJLTBZWRRB-UHFFFAOYSA-N 0.000 description 5
239000003921 oil Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000007884 disintegrant Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
238000003419 tautomerization reaction Methods 0.000 description 4
QILZDWMMWFCBPW-UHFFFAOYSA-N 3,4-difluorobenzene-1,2-diamine Chemical compound NC1=CC=C(F)C(F)=C1N QILZDWMMWFCBPW-UHFFFAOYSA-N 0.000 description 3
NZIHMSYSZRFUQJ-UHFFFAOYSA-N 6-chloro-1h-benzimidazole-2-carboxylic acid Chemical compound C1=C(Cl)C=C2NC(C(=O)O)=NC2=C1 NZIHMSYSZRFUQJ-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
229960004275 glycolic acid Drugs 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
150000004682 monohydrates Chemical class 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000012286 potassium permanganate Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 3
239000007921 spray Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
VFKGGGIPGOQNRO-UHFFFAOYSA-N (6-methoxy-1h-benzimidazol-2-yl)methanol Chemical compound COC1=CC=C2NC(CO)=NC2=C1 VFKGGGIPGOQNRO-UHFFFAOYSA-N 0.000 description 2
0 *OC(C(Cl)(Cl)Cl)=N Chemical compound *OC(C(Cl)(Cl)Cl)=N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
ZEWUAJSYSCUSJC-UHFFFAOYSA-N 2-(trichloromethyl)-6-(trifluoromethyl)-1h-benzimidazole Chemical compound FC(F)(F)C1=CC=C2NC(C(Cl)(Cl)Cl)=NC2=C1 ZEWUAJSYSCUSJC-UHFFFAOYSA-N 0.000 description 2
NFABQUNUXAXGBJ-UHFFFAOYSA-N 4-[(4-butoxyphenyl)iminomethyl]benzonitrile Chemical compound C1=CC(OCCCC)=CC=C1N=CC1=CC=C(C#N)C=C1 NFABQUNUXAXGBJ-UHFFFAOYSA-N 0.000 description 2
KWEWNOOZQVJONF-UHFFFAOYSA-N 4-fluorobenzene-1,2-diamine Chemical compound NC1=CC=C(F)C=C1N KWEWNOOZQVJONF-UHFFFAOYSA-N 0.000 description 2
GNKRJZXKNZQBJQ-UHFFFAOYSA-N 5,6-difluoro-2-(trichloromethyl)-1h-benzimidazole Chemical compound C1=C(F)C(F)=CC2=C1NC(C(Cl)(Cl)Cl)=N2 GNKRJZXKNZQBJQ-UHFFFAOYSA-N 0.000 description 2
FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 2
DAITVOCMWPNFTL-UHFFFAOYSA-N 5-methyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC=C2NC(C(O)=O)=CC2=C1 DAITVOCMWPNFTL-UHFFFAOYSA-N 0.000 description 2
GYPYWLKJBRSMIM-UHFFFAOYSA-N 6-methoxy-1h-benzimidazole-2-carboxylic acid Chemical compound COC1=CC=C2N=C(C(O)=O)NC2=C1 GYPYWLKJBRSMIM-UHFFFAOYSA-N 0.000 description 2
ZCDFRCAJGXZHBJ-UHFFFAOYSA-N 6-methyl-1h-benzimidazole-2-carboxylic acid Chemical compound CC1=CC=C2N=C(C(O)=O)NC2=C1 ZCDFRCAJGXZHBJ-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
UOHGHSPTKULKON-BETUJISGSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4,6-dimethyl-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(C)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1C UOHGHSPTKULKON-BETUJISGSA-N 0.000 description 2
SNTVUADMNDNQQT-PHIMTYICSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-fluoro-4-methyl-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1C SNTVUADMNDNQQT-PHIMTYICSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000003158 alcohol group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
150000007514 bases Chemical class 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000000132 electrospray ionisation Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960001031 glucose Drugs 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000010902 jet-milling Methods 0.000 description 2
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229960001855 mannitol Drugs 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 2
SVVJOSTYBXSNJB-TXEJJXNPSA-N methyl 2-[(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carbonyl]-3h-benzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC(C(=O)N3C[C@H]4CN(C)C[C@H]4C3)=NC2=C1 SVVJOSTYBXSNJB-TXEJJXNPSA-N 0.000 description 2
239000003595 mist Substances 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000003380 propellant Substances 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
235000015424 sodium Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
229960002920 sorbitol Drugs 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
238000012799 strong cation exchange Methods 0.000 description 2
239000012607 strong cation exchange resin Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
239000006068 taste-masking agent Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
235000012431 wafers Nutrition 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
NIWRFQPRPJVQLO-UHFFFAOYSA-N (6-chloro-1h-benzimidazol-2-yl)methanol Chemical compound C1=C(Cl)C=C2NC(CO)=NC2=C1 NIWRFQPRPJVQLO-UHFFFAOYSA-N 0.000 description 1
WFGVOSSDGZOYNE-UHFFFAOYSA-N (6-fluoro-1h-benzimidazol-2-yl)methanol Chemical compound C1=C(F)C=C2NC(CO)=NC2=C1 WFGVOSSDGZOYNE-UHFFFAOYSA-N 0.000 description 1
GUVUEQHXSSOYNR-UHFFFAOYSA-N (6-methyl-1h-benzimidazol-2-yl)methanol Chemical compound CC1=CC=C2N=C(CO)NC2=C1 GUVUEQHXSSOYNR-UHFFFAOYSA-N 0.000 description 1
DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
125000005859 (C1-C6)alkanoyloxymethyl group Chemical group 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
MAHAMBLNIDMREX-UHFFFAOYSA-N 1-methylindole-2-carboxylic acid Chemical compound C1=CC=C2N(C)C(C(O)=O)=CC2=C1 MAHAMBLNIDMREX-UHFFFAOYSA-N 0.000 description 1
RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
RHXSYTACTOMVLJ-UHFFFAOYSA-N 1H-benzimidazole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=NC2=C1 RHXSYTACTOMVLJ-UHFFFAOYSA-N 0.000 description 1
UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
FKCWIPFGJXWSCL-UHFFFAOYSA-N 2-(3-fluorophenyl)azepane Chemical compound FC1=CC=CC(C2NCCCCC2)=C1 FKCWIPFGJXWSCL-UHFFFAOYSA-N 0.000 description 1
YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
TWVXYERPFDJCQS-TXEJJXNPSA-N 2-[(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carbonyl]-3h-benzimidazole-5-carbonitrile Chemical compound N#CC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 TWVXYERPFDJCQS-TXEJJXNPSA-N 0.000 description 1
GGTHOTQUOFJXLR-PHIMTYICSA-N 2-[(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carbonyl]-3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 GGTHOTQUOFJXLR-PHIMTYICSA-N 0.000 description 1
PWOCRYSEVNPPKC-UHFFFAOYSA-N 2-fluoro-4-methyl-6-nitroaniline Chemical compound CC1=CC(F)=C(N)C([N+]([O-])=O)=C1 PWOCRYSEVNPPKC-UHFFFAOYSA-N 0.000 description 1
ZQEXBVHABAJPHJ-UHFFFAOYSA-N 2-fluoro-4-methylaniline Chemical compound CC1=CC=C(N)C(F)=C1 ZQEXBVHABAJPHJ-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
PEMNTZYICNLRSQ-UHFFFAOYSA-N 3,4,5,6-tetrafluorobenzene-1,2-diamine Chemical compound NC1=C(N)C(F)=C(F)C(F)=C1F PEMNTZYICNLRSQ-UHFFFAOYSA-N 0.000 description 1
WWDBSPRMQHYOOQ-UHFFFAOYSA-N 3,4,5-trifluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=C(F)C(F)=C1N WWDBSPRMQHYOOQ-UHFFFAOYSA-N 0.000 description 1
VWLLPPSBBHDXHK-UHFFFAOYSA-N 3,4-diaminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1N VWLLPPSBBHDXHK-UHFFFAOYSA-N 0.000 description 1
MHQULXYNBKWNDF-UHFFFAOYSA-N 3,4-dimethylbenzene-1,2-diamine Chemical compound CC1=CC=C(N)C(N)=C1C MHQULXYNBKWNDF-UHFFFAOYSA-N 0.000 description 1
YWPGZWRHHRUXEK-UHFFFAOYSA-N 3,5-dichlorobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=CC(Cl)=C1N YWPGZWRHHRUXEK-UHFFFAOYSA-N 0.000 description 1
QGNXDMSEEPNKCF-UHFFFAOYSA-N 3,5-difluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=CC(F)=C1N QGNXDMSEEPNKCF-UHFFFAOYSA-N 0.000 description 1
DMEPVFSJYHJGCD-UHFFFAOYSA-N 3,5-dimethylbenzene-1,2-diamine Chemical compound CC1=CC(C)=C(N)C(N)=C1 DMEPVFSJYHJGCD-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
ZFPIXTGBHCYNRN-UHFFFAOYSA-N 3-chloro-2-methyl-6-nitroaniline Chemical compound CC1=C(N)C([N+]([O-])=O)=CC=C1Cl ZFPIXTGBHCYNRN-UHFFFAOYSA-N 0.000 description 1
WLJOWNQBIYEBIP-UHFFFAOYSA-N 3-chloro-5-fluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=CC(Cl)=C1N WLJOWNQBIYEBIP-UHFFFAOYSA-N 0.000 description 1
UPFHQANNMQQOJI-UHFFFAOYSA-N 3-chloro-5-methylbenzene-1,2-diamine Chemical compound CC1=CC(N)=C(N)C(Cl)=C1 UPFHQANNMQQOJI-UHFFFAOYSA-N 0.000 description 1
TZBSPDKPSUCRTC-UHFFFAOYSA-N 3-fluoro-5-methylbenzene-1,2-diamine Chemical compound CC1=CC(N)=C(N)C(F)=C1 TZBSPDKPSUCRTC-UHFFFAOYSA-N 0.000 description 1
OJSCBKGRGMBEEW-UHFFFAOYSA-N 3-fluorobenzene-1,2-diamine Chemical compound NC1=CC=CC(F)=C1N OJSCBKGRGMBEEW-UHFFFAOYSA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
FLNGQEHVJVOTAU-UHFFFAOYSA-N 3-methyl-5-phenylmethoxy-1h-indole-2-carboxylic acid Chemical compound C1=C2C(C)=C(C(O)=O)NC2=CC=C1OCC1=CC=CC=C1 FLNGQEHVJVOTAU-UHFFFAOYSA-N 0.000 description 1
AXNUJYHFQHQZBE-UHFFFAOYSA-N 3-methylbenzene-1,2-diamine Chemical compound CC1=CC=CC(N)=C1N AXNUJYHFQHQZBE-UHFFFAOYSA-N 0.000 description 1
IWFHBRFJOHTIPU-UHFFFAOYSA-N 4,5-dichlorobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=C(Cl)C=C1N IWFHBRFJOHTIPU-UHFFFAOYSA-N 0.000 description 1
OJHZMCUKKPRVQS-UHFFFAOYSA-N 4,5-difluoro-2-(trichloromethyl)-1h-benzimidazole Chemical compound FC1=CC=C2N=C(C(Cl)(Cl)Cl)NC2=C1F OJHZMCUKKPRVQS-UHFFFAOYSA-N 0.000 description 1
XSZYBMMYQCYIPC-UHFFFAOYSA-N 4,5-dimethyl-1,2-phenylenediamine Chemical compound CC1=CC(N)=C(N)C=C1C XSZYBMMYQCYIPC-UHFFFAOYSA-N 0.000 description 1
HHMVFOMOMUMHJW-UHFFFAOYSA-N 4,5-dimethyl-2-(trichloromethyl)-1h-benzimidazole Chemical compound CC1=CC=C2N=C(C(Cl)(Cl)Cl)NC2=C1C HHMVFOMOMUMHJW-UHFFFAOYSA-N 0.000 description 1
NXCKYOGSYXCXGW-UHFFFAOYSA-N 4,6-dichloro-2-(trichloromethyl)-1h-benzimidazole Chemical compound ClC1=CC(Cl)=C2N=C(C(Cl)(Cl)Cl)NC2=C1 NXCKYOGSYXCXGW-UHFFFAOYSA-N 0.000 description 1
GDSCDZYMYMDVCW-UHFFFAOYSA-N 4,6-difluoro-2-(trichloromethyl)-1h-benzimidazole Chemical compound FC1=CC(F)=C2NC(C(Cl)(Cl)Cl)=NC2=C1 GDSCDZYMYMDVCW-UHFFFAOYSA-N 0.000 description 1
RQWJHUJJBYMJMN-UHFFFAOYSA-N 4-(trifluoromethyl)benzene-1,2-diamine Chemical compound NC1=CC=C(C(F)(F)F)C=C1N RQWJHUJJBYMJMN-UHFFFAOYSA-N 0.000 description 1
MJASWYJHGMJHER-UHFFFAOYSA-N 4-chloro-3-methylbenzene-1,2-diamine Chemical compound CC1=C(Cl)C=CC(N)=C1N MJASWYJHGMJHER-UHFFFAOYSA-N 0.000 description 1
BSMPRJISGCTCDC-UHFFFAOYSA-N 4-chloro-5-fluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=C(Cl)C=C1N BSMPRJISGCTCDC-UHFFFAOYSA-N 0.000 description 1
HOFKXNBVTNUDSH-UHFFFAOYSA-N 4-chloro-5-methylbenzene-1,2-diamine Chemical compound CC1=CC(N)=C(N)C=C1Cl HOFKXNBVTNUDSH-UHFFFAOYSA-N 0.000 description 1
CJXWSDLUJCNWCD-UHFFFAOYSA-N 4-chloro-6-fluoro-2-(trichloromethyl)-1h-benzimidazole Chemical compound FC1=CC(Cl)=C2N=C(C(Cl)(Cl)Cl)NC2=C1 CJXWSDLUJCNWCD-UHFFFAOYSA-N 0.000 description 1
HSINJNUXCKQGSC-UHFFFAOYSA-N 4-chloro-6-methyl-2-(trichloromethyl)-1h-benzimidazole Chemical compound CC1=CC(Cl)=C2NC(C(Cl)(Cl)Cl)=NC2=C1 HSINJNUXCKQGSC-UHFFFAOYSA-N 0.000 description 1
PSGAKWLMABPVAC-UHFFFAOYSA-N 4-fluoro-3-methylbenzene-1,2-diamine Chemical compound CC1=C(F)C=CC(N)=C1N PSGAKWLMABPVAC-UHFFFAOYSA-N 0.000 description 1
WMKGEQCSIZQIEK-UHFFFAOYSA-N 4-fluoro-5-(trifluoromethyl)benzene-1,2-diamine Chemical compound NC1=CC(F)=C(C(F)(F)F)C=C1N WMKGEQCSIZQIEK-UHFFFAOYSA-N 0.000 description 1
FUOSRKZBOIVBOS-UHFFFAOYSA-N 4-iodobenzene-1,2-diamine Chemical compound NC1=CC=C(I)C=C1N FUOSRKZBOIVBOS-UHFFFAOYSA-N 0.000 description 1
ZZAVIQXQBBOHBB-UHFFFAOYSA-N 4-methoxy-1h-indole-2-carboxylic acid Chemical compound COC1=CC=CC2=C1C=C(C(O)=O)N2 ZZAVIQXQBBOHBB-UHFFFAOYSA-N 0.000 description 1
AGAHETWGCFCMDK-UHFFFAOYSA-N 4-methoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1 AGAHETWGCFCMDK-UHFFFAOYSA-N 0.000 description 1
CTBHTPQCCMGLKI-UHFFFAOYSA-N 4-methyl-2-(trichloromethyl)-1h-benzimidazole Chemical compound CC1=CC=CC2=C1N=C(C(Cl)(Cl)Cl)N2 CTBHTPQCCMGLKI-UHFFFAOYSA-N 0.000 description 1
ILVWNVOYMNMQGW-UHFFFAOYSA-N 5,6-dichloro-2-(trichloromethyl)-1h-benzimidazole Chemical compound C1=C(Cl)C(Cl)=CC2=C1NC(C(Cl)(Cl)Cl)=N2 ILVWNVOYMNMQGW-UHFFFAOYSA-N 0.000 description 1
RYTOWTRCEGLIEY-UHFFFAOYSA-N 5,6-difluoro-1h-benzimidazole-2-carbonitrile Chemical compound C1=C(F)C(F)=CC2=C1NC(C#N)=N2 RYTOWTRCEGLIEY-UHFFFAOYSA-N 0.000 description 1
VVCCUBBNXURKEE-UHFFFAOYSA-N 5,6-difluoro-1h-benzimidazole-2-carboxylic acid Chemical compound FC1=C(F)C=C2NC(C(=O)O)=NC2=C1 VVCCUBBNXURKEE-UHFFFAOYSA-N 0.000 description 1
UZHQHNDRVITJPL-UHFFFAOYSA-N 5,6-dimethoxy-1h-indole-2-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC2=C1NC(C(O)=O)=C2 UZHQHNDRVITJPL-UHFFFAOYSA-N 0.000 description 1
OBHJZKBAYGTBSQ-UHFFFAOYSA-N 5,6-dimethyl-2-(trichloromethyl)-1h-benzimidazole Chemical compound C1=C(C)C(C)=CC2=C1NC(C(Cl)(Cl)Cl)=N2 OBHJZKBAYGTBSQ-UHFFFAOYSA-N 0.000 description 1
BIMHWDJKNOMNLD-UHFFFAOYSA-N 5-Hydroxyindole-2-carboxylic acid Chemical compound OC1=CC=C2NC(C(=O)O)=CC2=C1 BIMHWDJKNOMNLD-UHFFFAOYSA-N 0.000 description 1
YAULOOYNCJDPPU-UHFFFAOYSA-N 5-bromo-1h-indole-2-carboxylic acid Chemical compound BrC1=CC=C2NC(C(=O)O)=CC2=C1 YAULOOYNCJDPPU-UHFFFAOYSA-N 0.000 description 1
GSIHTVJIAVTOOI-UHFFFAOYSA-N 5-chloro-3-fluorobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=CC(F)=C1N GSIHTVJIAVTOOI-UHFFFAOYSA-N 0.000 description 1
LSDWHXDEMCMQHP-UHFFFAOYSA-N 5-chloro-3-methyl-1h-indole-2-carboxylic acid Chemical compound C1=C(Cl)C=C2C(C)=C(C(O)=O)NC2=C1 LSDWHXDEMCMQHP-UHFFFAOYSA-N 0.000 description 1
JCNVBPMFGXBWOI-UHFFFAOYSA-N 5-chloro-3-methylbenzene-1,2-diamine Chemical compound CC1=CC(Cl)=CC(N)=C1N JCNVBPMFGXBWOI-UHFFFAOYSA-N 0.000 description 1
GATWFBSYRFPZSV-UHFFFAOYSA-N 5-chloro-6-fluoro-2-(trichloromethyl)-1h-benzimidazole Chemical compound C1=C(Cl)C(F)=CC2=C1NC(C(Cl)(Cl)Cl)=N2 GATWFBSYRFPZSV-UHFFFAOYSA-N 0.000 description 1
WTXBRZCVLDTWLP-UHFFFAOYSA-N 5-fluoro-1H-indole-2-carboxylic acid Chemical compound FC1=CC=C2NC(C(=O)O)=CC2=C1 WTXBRZCVLDTWLP-UHFFFAOYSA-N 0.000 description 1
HGBKWCAURJPXQP-UHFFFAOYSA-N 5-fluoro-3-(trifluoromethyl)benzene-1,2-diamine Chemical compound NC1=CC(F)=CC(C(F)(F)F)=C1N HGBKWCAURJPXQP-UHFFFAOYSA-N 0.000 description 1
ZVUQPWOYWQFWQC-UHFFFAOYSA-N 5-fluoro-3-iodobenzene-1,2-diamine Chemical compound NC1=CC(F)=CC(I)=C1N ZVUQPWOYWQFWQC-UHFFFAOYSA-N 0.000 description 1
ZMHBFTVLCKJCML-UHFFFAOYSA-N 5-fluoro-4-methyl-2-(trichloromethyl)-1h-benzimidazole Chemical compound CC1=C(F)C=CC2=C1N=C(C(Cl)(Cl)Cl)N2 ZMHBFTVLCKJCML-UHFFFAOYSA-N 0.000 description 1
CPXMQDRGVOOXSQ-UHFFFAOYSA-N 5-methoxy-3-methyl-1h-indole-2-carboxylic acid Chemical compound COC1=CC=C2NC(C(O)=O)=C(C)C2=C1 CPXMQDRGVOOXSQ-UHFFFAOYSA-N 0.000 description 1
YEBJVSLNUMZXRJ-UHFFFAOYSA-N 5-methoxyindole-2-carboxylic acid Chemical compound COC1=CC=C2NC(C(O)=O)=CC2=C1 YEBJVSLNUMZXRJ-UHFFFAOYSA-N 0.000 description 1
BKPSJOSKWKTWAG-UHFFFAOYSA-N 6-chloro-1h-indole-2-carboxylic acid Chemical compound C1=C(Cl)C=C2NC(C(=O)O)=CC2=C1 BKPSJOSKWKTWAG-UHFFFAOYSA-N 0.000 description 1
MPRMQHVNLDBBTK-UHFFFAOYSA-N 6-chloro-4-methyl-2-(trichloromethyl)-1h-benzimidazole Chemical compound CC1=CC(Cl)=CC2=C1NC(C(Cl)(Cl)Cl)=N2 MPRMQHVNLDBBTK-UHFFFAOYSA-N 0.000 description 1
SUJPBSWQBUMNFS-UHFFFAOYSA-N 6-iodo-2-(trichloromethyl)-1h-benzimidazole Chemical compound IC1=CC=C2NC(C(Cl)(Cl)Cl)=NC2=C1 SUJPBSWQBUMNFS-UHFFFAOYSA-N 0.000 description 1
SCWBSQNVKBIKRY-UHFFFAOYSA-N 7-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=CC(F)=C2NC(C(=O)O)=CC2=C1 SCWBSQNVKBIKRY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
KWTJQJSBJGKFFU-IENPIDJESA-N CN(C1)CC(C2)[C@@H]1CN2C(c1nc(cc(c(F)c2)F)c2[nH]1)=O Chemical compound CN(C1)CC(C2)[C@@H]1CN2C(c1nc(cc(c(F)c2)F)c2[nH]1)=O KWTJQJSBJGKFFU-IENPIDJESA-N 0.000 description 1
VVARUVVNUZKWKR-VEDVMXKPSA-N CN(C1)CC(C2)[C@H]1CN2C(c([nH]c1c2)nc1cc(C(F)(F)F)c2F)=O Chemical compound CN(C1)CC(C2)[C@H]1CN2C(c([nH]c1c2)nc1cc(C(F)(F)F)c2F)=O VVARUVVNUZKWKR-VEDVMXKPSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
241000792859 Enema Species 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
229920002148 Gellan gum Polymers 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
ATFVTAOSZBVGHC-UHFFFAOYSA-N Glycolaldehyde dimer Chemical compound OC1COC(O)CO1 ATFVTAOSZBVGHC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
JBYPDQSOXKLICV-DTORHVGOSA-N [(3ar,6as)-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@H]4CNC[C@H]4C3)=NC2=C1 JBYPDQSOXKLICV-DTORHVGOSA-N 0.000 description 1
MEKPTWFKJCEIJF-PHIMTYICSA-N [(3ar,6as)-2-(2-hydroxyethyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)CCO)=NC2=C1 MEKPTWFKJCEIJF-PHIMTYICSA-N 0.000 description 1
DDBNPGXMUFTTNQ-BETUJISGSA-N [(3ar,6as)-2-ethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-1h-indol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)CC)=CC2=C1 DDBNPGXMUFTTNQ-BETUJISGSA-N 0.000 description 1
JSKDOTOZUCIGQR-PHIMTYICSA-N [(3ar,6as)-2-ethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)CC)=NC2=C1 JSKDOTOZUCIGQR-PHIMTYICSA-N 0.000 description 1
UAEQFWGTQBGJPK-OKILXGFUSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(1-methylindol-2-yl)methanone Chemical compound C1=CC=C2N(C)C(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 UAEQFWGTQBGJPK-OKILXGFUSA-N 0.000 description 1
LXVXLEBCNVNKBY-PHIMTYICSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(1h-benzimidazol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 LXVXLEBCNVNKBY-PHIMTYICSA-N 0.000 description 1
ABKXSGIRHHZKFH-OKILXGFUSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(3,5-dimethyl-1h-indol-2-yl)methanone Chemical compound N1C2=CC=C(C)C=C2C(C)=C1C(=O)N1C[C@@H]2CN(C)C[C@@H]2C1 ABKXSGIRHHZKFH-OKILXGFUSA-N 0.000 description 1
HZSBPGIRKQSPNB-KNVOCYPGSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4,5,6,7-tetrafluoro-1h-benzimidazol-2-yl)methanone Chemical compound FC1=C(F)C(F)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1F HZSBPGIRKQSPNB-KNVOCYPGSA-N 0.000 description 1
PLTTXTSVBINARI-BETUJISGSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4,5-dimethyl-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(C)C(C)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 PLTTXTSVBINARI-BETUJISGSA-N 0.000 description 1
GRGSRFKVOLGISE-TXEJJXNPSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4-methoxy-1h-indol-2-yl)methanone Chemical compound COC1=CC=CC2=C1C=C(C(=O)N1C[C@H]3CN(C)C[C@H]3C1)N2 GRGSRFKVOLGISE-TXEJJXNPSA-N 0.000 description 1
KWTJQJSBJGKFFU-DTORHVGOSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5,6-difluoro-1h-benzimidazol-2-yl)methanone Chemical compound FC1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 KWTJQJSBJGKFFU-DTORHVGOSA-N 0.000 description 1
STVYRGWVGJODKD-BETUJISGSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5,6-dimethyl-1h-benzimidazol-2-yl)methanone Chemical compound CC1=C(C)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 STVYRGWVGJODKD-BETUJISGSA-N 0.000 description 1
AFYTUNVHZHRXLZ-TXEJJXNPSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-1h-indol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 AFYTUNVHZHRXLZ-TXEJJXNPSA-N 0.000 description 1
BMQQPKJOEQQSCO-TXEJJXNPSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-3-methyl-1h-indol-2-yl)methanone Chemical compound N1C2=CC=C(Cl)C=C2C(C)=C1C(=O)N1C[C@@H]2CN(C)C[C@@H]2C1 BMQQPKJOEQQSCO-TXEJJXNPSA-N 0.000 description 1
UGGVOGPIDWSWJJ-PHIMTYICSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-fluoro-4-methyl-1h-benzimidazol-2-yl)methanone Chemical compound FC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1C UGGVOGPIDWSWJJ-PHIMTYICSA-N 0.000 description 1
OTISPXIRFCJWCV-BETUJISGSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-methoxy-1h-indol-2-yl)methanone Chemical compound COC1=CC=C2NC(C(=O)N3C[C@H]4CN(C)C[C@H]4C3)=CC2=C1 OTISPXIRFCJWCV-BETUJISGSA-N 0.000 description 1
RVYQLORIILMMFT-BETUJISGSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-methoxy-3-methyl-1h-indol-2-yl)methanone Chemical compound COC1=CC=C2NC(C(=O)N3C[C@H]4CN(C)C[C@H]4C3)=C(C)C2=C1 RVYQLORIILMMFT-BETUJISGSA-N 0.000 description 1
UEHSNDCPZZHPBK-OKILXGFUSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-methyl-1h-indol-2-yl)methanone Chemical compound CC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 UEHSNDCPZZHPBK-OKILXGFUSA-N 0.000 description 1
IBOXCUWZAMLMBI-KDURUIRLSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-phenylmethoxy-1h-indol-2-yl)methanone Chemical compound C([C@@H]1CN(C[C@@H]1C1)C)N1C(=O)C(NC1=CC=2)=CC1=CC=2OCC1=CC=CC=C1 IBOXCUWZAMLMBI-KDURUIRLSA-N 0.000 description 1
PFEOWGPIKBOASQ-PHIMTYICSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-methoxy-1h-benzimidazol-2-yl)methanone Chemical compound COC1=CC=C2NC(C(=O)N3C[C@H]4CN(C)C[C@H]4C3)=NC2=C1 PFEOWGPIKBOASQ-PHIMTYICSA-N 0.000 description 1
UZDBFBFSCJHUTO-OKILXGFUSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-methyl-1h-indol-2-yl)methanone Chemical compound C1=C(C)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 UZDBFBFSCJHUTO-OKILXGFUSA-N 0.000 description 1
QIGOVWKQCUWSMY-CALCHBBNSA-N [(3ar,6as)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-phenyl-1h-benzimidazol-2-yl)methanone Chemical compound C([C@@H]1CN(C[C@@H]1C1)C)N1C(=O)C(NC1=CC=2)=NC1=CC=2C1=CC=CC=C1 QIGOVWKQCUWSMY-CALCHBBNSA-N 0.000 description 1
RIMSKJWOXKZJML-OKILXGFUSA-N [(3ar,6as)-2-propan-2-yl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-1h-indol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C(C)C)=CC2=C1 RIMSKJWOXKZJML-OKILXGFUSA-N 0.000 description 1
MHMTXAAQGSUDGZ-PHIMTYICSA-N [(3as,6ar)-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-1h-indol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@H]4CNC[C@H]4C3)=CC2=C1 MHMTXAAQGSUDGZ-PHIMTYICSA-N 0.000 description 1
SUZMCTBMUTYOAD-OCAPTIKFSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4,5,6-trifluoro-1h-benzimidazol-2-yl)methanone Chemical compound FC1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1F SUZMCTBMUTYOAD-OCAPTIKFSA-N 0.000 description 1
KAZMUPAZDCLXBU-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4,5-difluoro-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(F)C(F)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 KAZMUPAZDCLXBU-DTORHVGOSA-N 0.000 description 1
NBRURPFKHWPZSN-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4,6-dichloro-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(Cl)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1Cl NBRURPFKHWPZSN-DTORHVGOSA-N 0.000 description 1
WOKLDSGZTYYBFY-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4,6-difluoro-1h-benzimidazol-2-yl)methanone Chemical compound FC1=CC(F)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 WOKLDSGZTYYBFY-DTORHVGOSA-N 0.000 description 1
MPBAPEHJJRNVNW-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4-chloro-6-fluoro-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1Cl MPBAPEHJJRNVNW-DTORHVGOSA-N 0.000 description 1
WRMBNHKFSZJISZ-PHIMTYICSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4-chloro-6-methyl-1h-benzimidazol-2-yl)methanone Chemical compound CC1=CC(Cl)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 WRMBNHKFSZJISZ-PHIMTYICSA-N 0.000 description 1
LKATZXWCHSWAIQ-AOOOYVTPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4-fluoro-1h-benzimidazol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1F LKATZXWCHSWAIQ-AOOOYVTPSA-N 0.000 description 1
ROTBSXQRAYGYHW-PHIMTYICSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4-fluoro-6-methyl-1h-benzimidazol-2-yl)methanone Chemical compound CC1=CC(F)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 ROTBSXQRAYGYHW-PHIMTYICSA-N 0.000 description 1
SQZWMHJWGPLOJA-TXEJJXNPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(4-methyl-1h-benzimidazol-2-yl)methanone Chemical compound C1=CC(C)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 SQZWMHJWGPLOJA-TXEJJXNPSA-N 0.000 description 1
QZMSSNWIMKHGLR-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5,6-dichloro-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=C(Cl)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 QZMSSNWIMKHGLR-DTORHVGOSA-N 0.000 description 1
DKILCFNFMJOGDY-BETUJISGSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5,6-dimethoxy-1h-indol-2-yl)methanone Chemical compound C1=C(OC)C(OC)=CC2=C1NC(C(=O)N1C[C@H]3CN(C)C[C@H]3C1)=C2 DKILCFNFMJOGDY-BETUJISGSA-N 0.000 description 1
GSIDUHNDWXWDRA-TXEJJXNPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-bromo-1h-indol-2-yl)methanone Chemical compound BrC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 GSIDUHNDWXWDRA-TXEJJXNPSA-N 0.000 description 1
NUYGJZTVDXBSTD-PHIMTYICSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-4-methyl-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1C NUYGJZTVDXBSTD-PHIMTYICSA-N 0.000 description 1
OYJJIFISASMYOC-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-6-fluoro-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 OYJJIFISASMYOC-DTORHVGOSA-N 0.000 description 1
KOJVCUSAMXNFEE-PHIMTYICSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-chloro-6-methyl-1h-benzimidazol-2-yl)methanone Chemical compound CC1=C(Cl)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 KOJVCUSAMXNFEE-PHIMTYICSA-N 0.000 description 1
JYPQQEAWLDRUPR-TXEJJXNPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-fluoro-1h-indol-2-yl)methanone Chemical compound FC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 JYPQQEAWLDRUPR-TXEJJXNPSA-N 0.000 description 1
PEHPRIJJBJXCCA-TXEJJXNPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(5-hydroxy-1h-indol-2-yl)methanone Chemical compound OC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 PEHPRIJJBJXCCA-TXEJJXNPSA-N 0.000 description 1
XWWUQTHQBUNBKK-AOOOYVTPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 XWWUQTHQBUNBKK-AOOOYVTPSA-N 0.000 description 1
QNRQKPKSXUBLSV-TXEJJXNPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-1h-indol-2-yl)methanone Chemical compound C1=C(Cl)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 QNRQKPKSXUBLSV-TXEJJXNPSA-N 0.000 description 1
BSKAXZVDJBKYQD-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-4-fluoro-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(Cl)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1F BSKAXZVDJBKYQD-DTORHVGOSA-N 0.000 description 1
OMMPMHJBWCBBBB-PHIMTYICSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-4-methyl-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=CC(C)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 OMMPMHJBWCBBBB-PHIMTYICSA-N 0.000 description 1
IVGCLIOMMNYKHZ-AOOOYVTPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-fluoro-1h-benzimidazol-2-yl)methanone Chemical compound FC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 IVGCLIOMMNYKHZ-AOOOYVTPSA-N 0.000 description 1
TZOZWAVCCVTGMK-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-fluoro-4-iodo-1h-benzimidazol-2-yl)methanone Chemical compound C1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1I TZOZWAVCCVTGMK-DTORHVGOSA-N 0.000 description 1
LMJOVMKHEVXDBT-AOOOYVTPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-iodo-1h-benzimidazol-2-yl)methanone Chemical compound IC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 LMJOVMKHEVXDBT-AOOOYVTPSA-N 0.000 description 1
CRQNSDFXSGOYJK-TXEJJXNPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-methyl-1h-benzimidazol-2-yl)methanone Chemical compound CC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 CRQNSDFXSGOYJK-TXEJJXNPSA-N 0.000 description 1
VSVWUFAFQMYPKV-TXEJJXNPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(7-fluoro-1h-indol-2-yl)methanone Chemical compound C1=CC(F)=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=CC2=C1 VSVWUFAFQMYPKV-TXEJJXNPSA-N 0.000 description 1
VVARUVVNUZKWKR-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[5-fluoro-6-(trifluoromethyl)-1h-benzimidazol-2-yl]methanone Chemical compound FC(F)(F)C1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 VVARUVVNUZKWKR-DTORHVGOSA-N 0.000 description 1
XVOTUGPTDQFZQO-AOOOYVTPSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]methanone Chemical compound FC(F)(F)C1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 XVOTUGPTDQFZQO-AOOOYVTPSA-N 0.000 description 1
XDRQUVMUASWBPY-DTORHVGOSA-N [(3as,6ar)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[6-fluoro-4-(trifluoromethyl)-1h-benzimidazol-2-yl]methanone Chemical compound C1=C(F)C=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1C(F)(F)F XDRQUVMUASWBPY-DTORHVGOSA-N 0.000 description 1
KHVBCLVNMVBPSB-TXEJJXNPSA-N [(3as,6ar)-2-propan-2-yl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-(6-chloro-1h-benzimidazol-2-yl)methanone Chemical compound ClC1=CC=C2NC(C(=O)N3C[C@@H]4CN(C[C@@H]4C3)C(C)C)=NC2=C1 KHVBCLVNMVBPSB-TXEJJXNPSA-N 0.000 description 1
CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
WRYNUJYAXVDTCB-UHFFFAOYSA-M acetyloxymercury Chemical compound CC(=O)O[Hg] WRYNUJYAXVDTCB-UHFFFAOYSA-M 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
238000010420 art technique Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229940077731 carbohydrate nutrients Drugs 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
KPNXFEQRRQVTRX-DTORHVGOSA-N chembl1915348 Chemical compound FC1=C(F)C=C2NC(C(=N)N3C[C@@H]4CN(C[C@@H]4C3)C)=NC2=C1 KPNXFEQRRQVTRX-DTORHVGOSA-N 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000002826 coolant Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
229950010286 diolamine Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940110377 dl- arginine Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-M ethanimidate Chemical compound CC([O-])=N DLFVBJFMPXGRIB-UHFFFAOYSA-M 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
235000010492 gellan gum Nutrition 0.000 description 1
239000000216 gellan gum Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940097042 glucuronate Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000005337 ground glass Substances 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
229950000177 hibenzate Drugs 0.000 description 1
239000003396 histamine H4 receptor antagonist Substances 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007916 intrasternal administration Methods 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
235000005772 leucine Nutrition 0.000 description 1
229960004873 levomenthol Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229960002160 maltose Drugs 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
RCXZSWHWZBTFGU-UHFFFAOYSA-N methyl 5,6-difluoro-1h-benzimidazole-2-carboxylate Chemical compound FC1=C(F)C=C2NC(C(=O)OC)=NC2=C1 RCXZSWHWZBTFGU-UHFFFAOYSA-N 0.000 description 1
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
WHXUSWHUWNRNHT-UHFFFAOYSA-N n-(2-fluoro-4-methylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1F WHXUSWHUWNRNHT-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000005487 naphthalate group Chemical group 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
239000002353 niosome Substances 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229950004864 olamine Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000003544 oxime group Chemical group 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000003672 processing method Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000002469 receptor inverse agonist Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000008137 solubility enhancer Substances 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
FYUVLZRRIRGSTE-DTORHVGOSA-N tert-butyl (3ar,6as)-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1NC[C@@H]2CN(C(=O)OC(C)(C)C)C[C@@H]21 FYUVLZRRIRGSTE-DTORHVGOSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
125000001302 tertiary amino group Chemical group 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
239000010409 thin film Substances 0.000 description 1
150000003556 thioamides Chemical class 0.000 description 1
230000009974 thixotropic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940074410 trehalose Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2007542155A 2004-11-24 2005-11-10 オクタヒドロピロロ［３，４−ｃ］ピロール誘導体 Pending JP2008520644A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04106044A EP1671972A1 (en)	2004-11-24	2004-11-24	Octahydropyrrolo[3,4-c]pyrrole derivatives
EP05100474		2005-01-26
PCT/IB2005/003478 WO2006056848A1 (en)	2004-11-24	2005-11-10	Octahydropyrrolo[3,4-c]pyrrole derivatives

Publications (1)

Publication Number	Publication Date
JP2008520644A true JP2008520644A (ja)	2008-06-19

Family

ID=35985757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2007542155A Pending JP2008520644A (ja)	2004-11-24	2005-11-10	オクタヒドロピロロ［３，４−ｃ］ピロール誘導体

Country Status (12)

Country	Link
EP (1)	EP1846409A1 (es)
JP (1)	JP2008520644A (es)
AR (1)	AR054707A1 (es)
CA (1)	CA2587141A1 (es)
GT (1)	GT200500340A (es)
NL (1)	NL1030503C2 (es)
PA (1)	PA8653801A1 (es)
PE (1)	PE20061055A1 (es)
SV (1)	SV2007002315A (es)
TW (1)	TW200626600A (es)
UY (1)	UY29221A1 (es)
WO (1)	WO2006056848A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011013752A1 (ja) *	2009-07-31	2011-02-03	塩野義製薬株式会社	縮合へテロ環誘導体を含有する医薬組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8012955B2 (en)	2006-12-28	2011-09-06	Rigel Pharmaceuticals, Inc.	N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
EP2201982A1 (en)	2008-12-24	2010-06-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Histamine H4 receptor antagonists for the treatment of vestibular disorders
CA2778484C (en)	2009-10-23	2018-07-31	Janssen Pharmaceutica Nv	Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
JP5848251B2 (ja)	2009-10-23	2016-01-27	ヤンセンファーマシューティカエヌ．ベー．	オレキシン受容体調節因子としての縮合複素環式化合物
EP2491034B1 (en)	2009-10-23	2013-12-18	Janssen Pharmaceutica, N.V.	Fused heterocyclic compounds as orexin receptor modulators
WO2012145581A1 (en)	2011-04-20	2012-10-26	Janssen Pharmaceutica Nv	Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
PT2858647T (pt)	2012-06-08	2018-10-03	Sensorion	Inibidores do recetor h4 para tratamento de tinido
CA2960253A1 (en)	2016-03-10	2017-09-10	Janssen Pharmaceutica Nv	Methods of treating depression using orexin-2 receptor antagonists
US11453676B2 (en)	2018-02-02	2022-09-27	Forward Therapeutics, Inc.	Inhibitors of protein arginine deiminases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2620341A (en) *	1949-03-24	1952-12-02	Burroughs Wellcome Co	N,n-dialkyl-quinoline-4-carboxamidines
KR100463771B1 (ko) *	1995-05-11	2005-05-16	파마시아 앤드 업존 캄파니 엘엘씨	스피로환식또는이환식디아지닐또는카바지닐옥사졸리디논
GB9902453D0 (en) *	1999-02-05	1999-03-24	Zeneca Ltd	Chemical compounds
BR0207952A (pt) *	2001-03-07	2004-07-27	Pfizer Prod Inc	Moduladores da atividade de receptores de quimiocina
EP1373204B1 (en) *	2001-03-09	2016-10-26	Janssen Pharmaceuticals, Inc.	Heterocyclic compounds
EP1543011B1 (en) *	2002-09-06	2006-05-03	Janssen Pharmaceutica N.V.	Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
CA2497788A1 (en) *	2002-09-06	2004-03-18	Janssen Pharmaceutica, N.V.	Use of histamine h4 receptor modulators for the treatment of allergy and asthma
PL377087A1 (pl) *	2002-09-06	2006-01-23	Janssen Pharmaceutica, N.V.	Związki heterocykliczne

2005
- 2005-11-10 JP JP2007542155A patent/JP2008520644A/ja active Pending
- 2005-11-10 CA CA002587141A patent/CA2587141A1/en not_active Abandoned
- 2005-11-10 EP EP05824102A patent/EP1846409A1/en not_active Withdrawn
- 2005-11-10 WO PCT/IB2005/003478 patent/WO2006056848A1/en active Application Filing
- 2005-11-21 PE PE2005001360A patent/PE20061055A1/es not_active Application Discontinuation
- 2005-11-21 UY UY29221A patent/UY29221A1/es not_active Application Discontinuation
- 2005-11-22 AR ARP050104891A patent/AR054707A1/es unknown
- 2005-11-23 GT GT200500340A patent/GT200500340A/es unknown
- 2005-11-23 TW TW094141134A patent/TW200626600A/zh unknown
- 2005-11-23 NL NL1030503A patent/NL1030503C2/nl not_active IP Right Cessation
- 2005-11-24 SV SV2005002315A patent/SV2007002315A/es not_active Application Discontinuation
- 2005-11-24 PA PA20058653801A patent/PA8653801A1/es unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011013752A1 (ja) *	2009-07-31	2011-02-03	塩野義製薬株式会社	縮合へテロ環誘導体を含有する医薬組成物

Also Published As

Publication number	Publication date
AR054707A1 (es)	2007-07-11
CA2587141A1 (en)	2006-06-01
WO2006056848A1 (en)	2006-06-01
SV2007002315A (es)	2007-02-16
UY29221A1 (es)	2006-06-30
PA8653801A1 (es)	2006-06-02
GT200500340A (es)	2006-07-13
PE20061055A1 (es)	2006-11-09
TW200626600A (en)	2006-08-01
NL1030503A1 (nl)	2006-05-29
EP1846409A1 (en)	2007-10-24
NL1030503C2 (nl)	2006-11-28

Publication	Publication Date	Title
KR100908155B1 (ko)	2009-07-16	히스타민 ｈ3 수용체 리간드로서 유용한테트라하이드로나프티리딘 유도체
US10858373B2 (en)	2020-12-08	Heterocyclic spiro compounds as MAGL inhibitors
JP5608162B2 (ja)	2014-10-15	疾患を治療するのに有用なトリアゾール誘導体
US10626125B2 (en)	2020-04-21	1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors
CN112566916B (zh)	2023-10-20	作为pad4抑制剂的经取代的噻吩并吡咯
KR20120025010A (ko)	2012-03-14	피리미딘 유도체
JP2018527329A (ja)	2018-09-20	Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
JP2002517445A (ja)	2002-06-18	ｃＧＭＰホスホジエステラーゼのキナゾリノン抑制剤
JP2009526037A (ja)	2009-07-16	トリアゾロピリジン化合物
NZ548097A (en)	2008-12-24	5,7-diaminopyrazolo[4,3-d]pyrimidines with PDE-5 inhibiting activity
JP2008533193A (ja)	2008-08-21	オキシトシン拮抗薬としての置換トリアゾール誘導体
US20060111416A1 (en)	2006-05-25	Octahydropyrrolo[3,4-C]pyrrole derivatives
WO2007034278A2 (en)	2007-03-29	Fused imidazole derivatives as c3a receptor antagonists
WO2007034277A1 (en)	2007-03-29	Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
TW200533351A (en)	2005-10-16	Compounds for the treatment of diseases
JP2007505888A (ja)	2007-03-15	オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2008520644A (ja)	2008-06-19	オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
WO2007045989A1 (en)	2007-04-26	Pyridyl derivatives useful as h3 ligands
JP2008501775A (ja)	2008-01-24	オキシトシン拮抗剤としての置換トリアゾール誘導体
CN113754635A (zh)	2021-12-07	稠环类化合物及其制备方法和用途
JP2007532526A (ja)	2007-11-15	ピラゾロ［４，３−ｄ］ピリミジン類
EP1671972A1 (en)	2006-06-21	Octahydropyrrolo[3,4-c]pyrrole derivatives
TWI753550B (zh)	2022-01-21	經取代的1,3-苯基雜芳基衍生物及其在治療疾病中之用途
JP2009504628A (ja)	2009-02-05	オキシトシン拮抗薬としての置換トリアゾール誘導体
US20050004200A1 (en)	2005-01-06	Pyrazole compounds as integrin receptor antagonists derivatives

JP2008520644A - オクタヒドロピロロ［３，４−ｃ］ピロール誘導体 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=35985757

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (9)

Family Cites Families (8)

Cited By (1)

Also Published As

Similar Documents